Instrument Inactif

Gouvernance Mateon Therapeutics Inc OTC Bulletin Board

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board
- ^USD	-

13/08	Oncotelic Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
07/07	Oncotelic Therapeutics, Inc. et Sapu Nano (US) LLC font progresser leur programme clinique conjoint et étendent leurs sites cliniques en Europe	CI

Comité Exécutif: Mateon Therapeutics Inc

Dirigeant

Fonctions occupéesDepuis

Vuong Trieu

61 ans

Chief Executive Officer	22/04/2019
President	22/04/2019

Amit Bhupendra Shah

59 ans

Director of Finance/CFO

01/07/2019

Anthony Maida

61 ans

Chief Tech/Sci/R&D Officer

11/05/2020

Seymour H. Fein

77 ans

Chief Tech/Sci/R&D Officer	28/02/2023
General Counsel	04/05/2022

Composition du Conseil d'Administration: Mateon Therapeutics Inc

Administrateur

ComitésDepuis

Vuong Trieu

61 ans

Chairman

22/04/2019

Anthony Maida

61 ans

Audit Committee	11/05/2020
Governance Committee	11/05/2020
Nominating Committee	11/05/2020
Compensation Committee Chair	11/05/2020

Steven King

61 ans

Compensation Committee	11/05/2020
Governance Committee Chair	11/05/2020
Nominating Committee Chair	11/05/2020

Anciens Dirigeants et Administrateurs: Mateon Therapeutics Inc

Insider

Fonctions occupées

DepuisJusqu'au

David Diamond

Director/Board Member	22/01/2020	16/07/2021
Independent Dir/Board Member	22/01/2020	16/07/2021

Chulho Park

Chief Tech/Sci/R&D Officer

22/04/2019

01/07/2021

William Schwieterman

Director/Board Member	22/04/2019	15/01/2020
Chief Executive Officer	12/05/2015	22/04/2019
Chairman	18/08/2016	22/04/2019
Independent Dir/Board Member	01/06/2007	12/05/2015
President	12/05/2015	22/04/2019

Fatih Uckun

Chief Tech/Sci/R&D Officer	22/04/2019	06/01/2020
Chief Tech/Sci/R&D Officer	03/05/2022	28/02/2023

Matthew M. Loar

Comptroller/Controller/Auditor	20/07/2015	22/04/2019
Director of Finance/CFO	20/07/2015	30/06/2019
Investor Relations Contact	20/07/2015	30/06/2019
Corporate Secretary	22/04/2019	30/06/2019

Bobby Sandage

Director/Board Member	25/10/2016	22/04/2019
Independent Dir/Board Member	25/10/2016	22/04/2019

Donald R. Reynolds

Director/Board Member	25/10/2016	22/04/2019
Independent Dir/Board Member	25/10/2016	22/04/2019

Simon Pedder

Director/Board Member	21/03/2016	10/04/2019
Independent Dir/Board Member	21/03/2016	10/04/2019

Tamar Howson

Director/Board Member	02/04/2010	01/01/2018
Independent Dir/Board Member	02/04/2010	01/01/2018

Jeffrey Nelson

Corporate Officer/Principal

01/01/2015

01/01/2017

Gerald McMahon

Director/Board Member	12/09/2011	23/11/2016
Independent Dir/Board Member	09/09/2011	23/11/2016

Barbara Riching

Director of Finance/CFO	31/07/2012	03/06/2015
Corporate Officer/Principal	01/12/2011	31/07/2012

Peter J. Langecker

Director/Board Member	02/03/2011	15/05/2014
Chief Executive Officer	01/06/2009	15/05/2014
Chairman	29/12/2011	02/01/2014
Independent Dir/Board Member	01/06/2009	30/05/2012
Corporate Officer/Principal	19/06/2009	11/10/2009
President	11/10/2009	15/05/2014

Alastair J. J. Wood

Director/Board Member

22/10/2008

16/07/2013

David Louis Johnson

Comptroller/Controller/Auditor	31/03/2012	30/07/2012
Director of Finance/CFO	31/03/2012	30/07/2012

James Murphy

Comptroller/Controller/Auditor	07/03/2011	29/12/2011
Director of Finance/CFO	01/03/2004	31/03/2012

Alice M. Varga

General Counsel

01/02/2012

Bill N. Shiebler

Director/Board Member

01/01/2002

01/01/2012

Kathleen M. Lee

Corporate Officer/Principal

01/01/2012

Mark Kessel

Director/Board Member

22/10/2008

09/09/2011

Michelle Edwards

Public Communications Contact

01/12/2007

01/09/2011

David Chaplin

Director/Board Member	07/03/2011	30/08/2011
Chief Tech/Sci/R&D Officer	01/07/2000	30/08/2011
Director/Board Member	23/01/2013	22/04/2019
Chief Executive Officer	15/05/2014	12/05/2015
Chief Tech/Sci/R&D Officer	13/05/2015	22/04/2019
Independent Dir/Board Member	01/01/2018	-
President	15/05/2014	12/05/2015

Roy Fickling

Director/Board Member

01/06/2007

31/03/2011

Arthur Laffer

Director/Board Member

01/06/1998

11/03/2010

John Kollins

Director/Board Member	01/10/2008	08/10/2009
Chief Executive Officer	01/10/2008	08/10/2009
Chief Operating Officer	01/07/2008	01/10/2008

Joel-Tomas Citron

Chairman

01/01/2002

28/05/2009

Patricia Ann Walicke

Chief Tech/Sci/R&D Officer

31/07/2007

29/04/2009

Richard Chin

Chief Executive Officer	01/07/2006	22/10/2008
President	01/07/2006	22/10/2008
Corporate Secretary	01/07/2006	22/10/2008

J. Richard Zecher

Director/Board Member

01/01/2008

Jai Balkissoon

Chief Tech/Sci/R&D Officer

01/01/2008

Peter A. Harris

Chief Tech/Sci/R&D Officer

01/06/2001

31/08/2007

Fred Driscoll

Chief Executive Officer	01/01/2000	30/06/2006
Chairman	01/01/2000	30/06/2006
President	01/01/2000	30/06/2006

Björn Nordenvall

Director/Board Member	01/03/1995	01/01/2002
Chief Executive Officer	01/06/1995	01/01/2002
President	01/03/1995	-

Per-Olof Ragnar Söderberg

Director/Board Member

01/10/1997

Scott L. Young

Chief Operating Officer	01/01/1997	-
Chief Operating Officer	-	14/08/2006

Susan T. Hager

Public Communications Contact

Agneta Svedberg

Corporate Officer/Principal

Jodie Crowley

Human Resources Officer

Harri V. Taranto

Director/Board Member

21/08/2009

Claus Juan Møller-San Pedro

Chief Operating Officer	-	-
Chief Tech/Sci/R&D Officer	-	-

Heather Faulds

General Counsel

Sten Lindahl

Director/Board Member

Ronald W. Pero

Corporate Officer/Principal

Richard A. Brown

Chairman

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	6
Femme	0

Dont comité exécutif

Homme	4
Femme	0

Dont Administrateurs

Homme	3
Femme	0

Oncotelic Therapeutics, Inc. est une société biopharmaceutique au stade clinique qui se consacre au développement de médicaments destinés au traitement d’indications oncologiques orphelines, en mettant au point des médicaments antisens et des médicaments injectables à base de petites molécules pour le traitement du cancer. La société dispose de trois programmes phares de médicaments et de technologies d'IA : AL-101 – Médicament intranasal et système d'administration d'apomorphine par voie intranasale pour le traitement de la maladie de Parkinson (MP), de la dysfonction érectile (DE) et de la dysfonction sexuelle féminine (DSF) ; CA4P – un agent disruptif vasculaire (VDA) – en association avec l’ipilimumab pour le traitement des tumeurs solides, en particulier le mélanome chez l’adulte et l’enfant ; Oxi4503 – un VDA de deuxième génération – pour le traitement des tumeurs hématologiques, en particulier la leucémie infantile ; OT-101 – un antisens dirigé contre le TGF-b2 – pour le traitement de divers cancers et de divers virus, et l’artémisinine – un dérivé naturel de l’herbe asiatique Artemisia annua.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société